DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

Information source: Drexel University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Nausea; Vomiting

Intervention: Aprepitant (Drug); Scopolamine (Drug)

Phase: N/A

Status: Completed

Sponsored by: Drexel University College of Medicine

Official(s) and/or principal investigator(s):
Jay Horrow, MD, Study Director, Affiliation: Drexel University College of Medicine


Recent evidence suggests multiple drug therapy is superior to single agents. The study compares the incidence of nausea, vomiting, need for rescue medication, prolonged PACU time, and unplanned hospital admission in patients with high risk for PONV treated with oral aprepitant with or without transdermal scopolamine preoperatively.

Clinical Details

Official title: A Randomized, Double-blind Comparison of Oral Aprepitant Alone Versus Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care

Primary outcome: Number of Participants With Postoperative Nausea and Vomiting

Detailed description: Postoperative nausea and vomiting (PONV) is a serious problem complicating surgery. PONV has an overall incidence of 30% and a 70% incidence in high-risk patients. PONV yields unplanned hospital admission, pulmonary aspiration, esophageal rupture, electrolyte abnormalities, dehydration, and delayed discharge from the postanesthesia care unit (PACU). Additional use of resources costs the health care industry hundreds of millions of dollars annually. Patient satisfaction is greatly improved when PONV is prevented. 4 PONV etiology is multifactorial and the treatment is multimodal.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Patient must be between 18 and 65 years of age.

- Patient's ASA (American Society of Anesthesiologist) class must be between 1 and 3.

- If patient is currently on oral contraceptive to prevent pregnancy, she must be

willing to use a back up form of birth control for one month post study.

- Patient must have 1 FACTOR to qualify

- Female Sex

- History of PONV

- Motion Sickness

- Non-Smoker

- Intended Use of Post Operative Opioids

Exclusion Criteria:

- Patients with a history of vomiting due to middle ear infection, nervous system

disorder, or any other condition.

- The surgical procedure is less than 1 hour.

- The patient is pregnant or breast feeding.

- The patient has taken antiemetic medication in previous 24 hours.

- Patients with narrow-angle glaucoma.

- Allergy to belladonna alkaloids.

- Hypersensitivity to barbiturates.

- Patient taking any of the following medications:

- Orap

- Seldane

- Hismanal

- Propulsid

- Phenytoin

- Phenothiazines

- Tricyclic Antidepressants

- Meperidine

- Tolbutamide

- Aluminum and Magnesium Trisilicate-containing Antacids

- Anti-Cholinergics

- Coumadin

- Male patients with prostate hypertrophy.

- Patients with severe hepatic disease.

- Patients on Chemotherapy and taking Aprepitant.

- Patients with fever.

- Patients with sepsis.

Locations and Contacts

Hahnemann University Hospital, Philadelphia, Pennsylvania 19102, United States
Additional Information

Starting date: April 2008
Last updated: May 1, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017